Over the past five years, generic prescriptions have accounted for a larger share of total prescriptions dispensed, and Canadian generics have consistently been more expensive, thus boosting industry revenue. In addition, increased merger and acquisition activity has strengthened industry profitability as companies benefit from economies of scale. Over the next five years, provincial and territorial regulations for generic drug prices will likely become more stringent, dampening industry revenue growth. However, as biologic drugs lose their patent exclusivity, more biosimilar drugs will be able to enter the market, boosting industry revenue.
This industry develops prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals. Generic drugs are produced and distributed without patent protection and industry operators are not significantly engaged in the research and development of new drugs. The industry does not include manufacturers of nutritional supplements or cosmetic beauty products.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.